ライフサイエンスコーパス: JAK3

1 protein kinase (prkdc), and janus kinase 3 (jak3).

2 xploit a unique cysteine (Cys909) residue in JAK3.

3 mains of Shc were responsible for binding to Jak3.

4 d PTP1B to Jak3 and thereby dephosphorylated Jak3.

5 ne phosphorylate and functionally inactivate Jak3.

6 esin) domain and induced gain of function in JAK3.

7 trols and found 4 patients with mutations in JAK3.

8 ta-catenin facilitated its interactions with Jak3.

9 e residues on beta-catenin phosphorylated by Jak3.

10 r further phosphorylation of beta-catenin by Jak3.

11 flunomide, inhibits the activity of JAK1 and JAK3.

12 via a direct interaction with phosphorylated JAK3.

13 ovided exceptional selectivity for JAK2 over JAK3 (23).

14 We screened our compound library against JAK3, a key signaling kinase in immune cells, and identi

15 amma) as a critical growth determinant for a JAK3(A572V) mutation-positive acute myeloid leukemia cel

16 letely abrogated the clonogenic potential of JAK3(A572V), as well as the transforming potential of ad

17 JAK3, whereas cells that originally showed a JAK3-activating mutation became resistant to inhibitors

18 as the transforming potential of additional JAK3-activating mutations such as JAK3(M511I).

19 e trans-molecular mechanism of regulation of Jak3 activation by Shc.

20 e mechanism of trans-molecular regulation of Jak3 activation is not known.

21 lar mechanism of intracellular regulation of Jak3 activation where Jak3 interactions with Shc acted a

22 beta and gammac chain, consequently blocking Jak3 activation.

23 than previously determined is necessary for JAK3 activation/gammaC-mediated signaling in response to

24 ses and can potently (IC50 < 100 nm) inhibit Jak3 activity in cell-based assays.

25 Thus, pharmacological inhibition of JAK3 activity may provide a promising treatment option f

26 suggesting that Fsk can negatively regulate Jak3 activity possibly mediated through PKA.

27 Inhibition of JAK3 activity reduced the phosphorylation of cPLA2 and C

28 by chemokines is also dependent on JAK2 and JAK3 activity.

29 tion of an additional mutation in the mutant JAK3 allele.

30 Lack of Jak3 also resulted in exaggerated symptoms of metabolic

31 nants that regulate the interactions between Jak3 and cytoskeletal proteins of the villin/gelsolin fa

32 molecular mechanism of interactions between Jak3 and cytoskeletal proteins where tyrosine phosphoryl

33 olecular switch for the interactions between Jak3 and cytoskeletal proteins.

34 te-limiting step during interactions between Jak3 and cytoskeletal proteins.

35 wn of IL2Rgamma abrogates phosphorylation of JAK3 and downstream signaling molecules, JAK1, STAT5, MA

36 onstrate the negative regulatory function of JAK3 and elucidate the signaling pathway by which JAK3 d

37 Whereas JAK3 and Fes marginally activate PLD2 in non-transformed

38 Cytokine signaling dependent on JAK3 and JAK1 is critically important in chronic inflamm

39 ib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1.

40 rylation of the signaling molecules Jak1 and Jak3 and negative regulation of signaling via Jak and th

41 highlights a unique signaling axis in which JAK3 and p38 MAPK regulate the activity of multiple enzy

42 are especially sensitive to a combination of JAK3 and PLD2 enzymatic activity inhibitors (30nM apigen

43 We also consistently found that JAK3 and PLD2 pathways are utilized at the maximum effic

44 nants that regulate the interactions between Jak3 and Shc and demonstrate the trans-molecular mechani

45 Direct interactions between mutants of Jak3 and Shc showed that although FERM domain of Jak3 wa

46 its and promoted tyrosine phosphorylation of Jak3 and STAT5.

47 vulnerabilities in T-ALL cells with combined JAK3 and SUZ12 mutations.

48 ulation that exists between the two kinases (JAK3 and the oncogene Fes) and between these two kinases

49 ated by PLD2 under direct regulation of both JAK3 and the tyrosine kinase, epidermal growth factor re

50 ited tyrosine phosphatases SHP2 and PTP1B to Jak3 and thereby dephosphorylated Jak3.

51 e genes encoding two of the four human JAKs (JAK3 and TYK2) and three of the six human STATs (STAT1,

52 Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine signals in

53 through direct interactions of Shc with both Jak3 and tyrosine phosphatases.

54 f cytokines, which mediate signaling through JAK3 and various downstream pathways to regulate lymphop

55 on of cell invasion by two kinases (EGFR and JAK3) and a phospholipase (PLD2) provides regulatory fle

56 etected by Western blot phosphorylated Jak1, Jak3, and a phosphotyrosine signal attributed to the gam

57 ting IL-2R complex formation, recruitment of JAK3, and activation of AKT and ERK1/2 and a transcripti

58 icate that HuR is tyrosine-phosphorylated by JAK3, and link this modification to HuR subcytoplasmic l

59 t expressed several genes including ALDH1A1, JAK3, and MMP15, whose functions were unknown in AML.

60 Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multipl

61 ctive sites of the four members (Jak1, Jak2, Jak3, and Tyk2), developing selective inhibitors within

62 JAK1 and JAK3 are recurrently mutated in acute lymphoblastic leuk

63 The products of the oncogene Fes and JAK3 are tyrosine kinases, whose expressions are elevate

64 Mutations in Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, b

65 Moreover, our results reveal a role of JAK3 as a potential suppressor for melanoma metastasis.

66 lin and that tyrosine autophosphorylation of Jak3 at the SH2 domain decreased these intramolecular in

67 We show that Jak3 autophosphorylation was the rate-limiting step duri

68 villin/gelsolin-wt as substrate showed that Jak3 autophosphorylation was the rate-limiting step duri

69 We demonstrate that Jak3 autophosphorylation was the rate-limiting step duri

70 ful selective agents, both as tools to probe Jak3 biology and potentially as therapies for autoimmune

71 action studies indicated that phosphorylated Jak3 bound to phosphorylated beta-catenin with a dissoci

72 sulted in elevated serine phosphorylation of Jak3 but not Stat5, suggesting that Fsk can negatively r

73 in NP (FOXP3, TGFB1, IL10, SMAD3, IL2RA, and JAK3), but transcription factors associated with Th2 (GA

74 ed through the activation of Janus kinase 3 (JAK3) by the vitamin K3 analog menadione.

75 Our data suggest that wild-type JAK3 competes with mutant JAK3 (M511I) for binding to th

76 ssion of IL2Rgamma, indicating IL2Rgamma and JAK3 contribute to constitutive JAK/STAT signaling throu

77 e combined immunodeficiency, but hypomorphic JAK3 defects can result in a milder clinical phenotype,

78 es from SCID patients with IL-2RG (n = 3) or JAK3 deficiency (n = 2), which produce similar "T-NK-B+"

79 impaired B-cell responses after HCT in IL2RG/JAK3 deficiency results from poor donor B-cell engraftme

80 y and to restore antibody responses in IL2RG/JAK3-deficient patients after HCT.

81 ruiting the E2 enzymes, were able to prevent JAK3 degradation induced by both ASB2/SKP2 and NOTCH sig

82 ral Janus kinase inhibitor that targets Jak1/Jak3 dependent Stat activation, has been assessed as a s

83 gamma chain cytokines and a Janus kinase 3 (JAK3)-dependent pathway in malignant T cells, and blocke

84 lymphocyte-specific protein tyrosine kinase/JAK3-dependent activation of the PI3K/AKT pathway with l

85 seful tools to pharmacologically interrogate JAK3-dependent biology.

86 on through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), dem

87 interactions with Shc acted as regulators of Jak3 dephosphorylation through direct interactions of Sh

88 and elucidate the signaling pathway by which JAK3 differentially regulates TLR-mediated inflammatory

89 trans-phosphorylation of beta-catenin, where Jak3 directly phosphorylated three tyrosine residues, vi

90 ring Jak3 trans-phosphorylation of Shc where Jak3 directly phosphorylated two tyrosine residues in Sr

91 ive compounds are irreversible inhibitors of Jak3 enzyme activity in vitro.

92 The relatively rapid resynthesis rate of the JAK3 enzyme presented a unique challenge in the design o

93 Specific targeting of zebrafish Jak3 exerted a similar effect on lymphopoiesis, whereas

94 Interestingly, the R980W mutant of JAK3 exhibited diminished interaction with SKP2 and resi

95 titutive JAK3 mutant signaling by increasing JAK3 expression and phosphorylation.

96 We observed that reduced intestinal JAK3 expression during human obesity or JAK3 knockout in

97 Jak3 expression in these cells was essential for AJ loca

98 nt growth and were not affected by wild-type JAK3 expression.

99 In summary, the JAK3, Fes and PLD2 interactions in transformed cells mai

100 A new JAK3-Fes-PLD2 axis is responsible for the highly prolife

101 Modulating this new JAK3-Fes-PLD2 pathway could be important to control the

102 domains of nonphosphorylated Jak3 prevented Jak3 from binding to villin and that tyrosine autophosph

103 l maturation/differentiation requires intact JAK3 function, even if partially functioning T lymphocyt

104 Although mutations that abrogate Jak3 functions cause different immunological disorders,

105 ibitors or specific small interfering RNA or JAK3 gene knockout resulted in an increase in TLR-mediat

106 also identified, including in the PDGFRA and JAK3 genes.

107 NOTCH signaling leads to the degradation of JAK3 in B lineage cells, suggesting that NOTCH signaling

108 Investigating JAK3 in cancer cells led to an important discovery as ex

109 A 2.9 A cocrystal structure of JAK3 in complex with 9 confirms the covalent interaction

110 reviously, we characterized the functions of Jak3 in cytoskeletal remodeling, epithelial wound healin

111 rome, present studies determined the role of Jak3 in development of such conditions.

112 Consistent with a role of JAK3 in GVHD, Jak3(-/-) T cells caused less severe GVHD.

113 ults reveal a new anti-inflammatory role for JAK3 in innate immune cells and show that the underlying

114 of PI3K enhanced this regulatory ability of JAK3 in LPS-stimulated monocytes.

115 However, the role of Jak3 in mucosal differentiation and inflammatory bowel d

116 In this report, we characterize the role of Jak3 in mucosal differentiation, basal colonic inflammat

117 requirement for signaling through IL-2RG and JAK3 in normal development of human lymphoid progenitors

118 se results demonstrate the essential role of Jak3 in promoting mucosal tolerance through suppressed e

119 results in loss of mature T and B cells and jak3 in T and putative Natural Killer cells.

120 se results demonstrate the essential role of Jak3 in the colon where it facilitated mucosal different

121 lis enhances the activity of Janus kinase 3 (JAK3) in innate immune cells, and subsequently phospho-i

122 ely, we found that mutant, but not wild-type JAK3, increased the expression of IL2Rgamma, indicating

123 Specifically, JAK3 inhibition by pharmacological inhibitors or specifi

124 Moreover, JAK3 inhibition correlated with an increased CD4(+) T ce

125 In this study, we found that JAK3 inhibition enhanced TLR-mediated immune responses b

126 ated periodontal disease model, we show that JAK3 inhibition enhances infiltration of inflammatory ce

127 JAK3 inhibition exhibited a GSK3 activity-dependent abil

128 rstood, although the suppressive function of JAK3 inhibition in adaptive immune response has been wel

129 tion of GSK3beta abrogated the capability of JAK3 inhibition to enhance proinflammatory cytokines and

130 e risk of immune suppression associated with JAK3 inhibition was undertaken.

131 herein are the first studies on the use of a JAK3 inhibitor in lentivirus infected NHP.

132 Treatment with a JAK3 inhibitor significantly reduced CTCL cell survival.

133 Recent findings show that the JAK3 inhibitor utilized in the studies reported herein h

134 ing our unique FLT3 substrate and identified JAK3 inhibitor VI (designated JI6 hereafter) as a novel

135 Consistently, JAK3 inhibitor was able to significantly reduce the grow

136 ecernotinib), a novel, potent, and selective JAK3 inhibitor, which demonstrates good efficacy in vivo

137 and blocked by tofacitinib, a clinical-grade JAK3 inhibitor.

138 infection, use was made of a Janus kinase 3 (JAK3) inhibitor that has previously been shown to be eff

139 of this family stimulated the development of JAK3 inhibitors and present an overview of current strat

140 esults warrant further investigation of JAK1/JAK3 inhibitors for the treatment of T-ALL.

141 decades, identification of highly selective JAK3 inhibitors has eluded the scientific community.

142 n of 2,4-substituted pyrimidines as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909)

143 ned and characterized substituted, tricyclic Jak3 inhibitors that selectively avoid inhibition of the

144 nted with neutralizing anti-IL-2 Ab or STAT5/JAK3 inhibitors, indicating that STAT5 signaling drives

145 Previously, we demonstrated that Jak3 interacted with actin-binding protein villin, there

146 and human intestinal epithelial cells where Jak3 interacted with and activated p85, the regulatory s

147 d 41, ezrin, radixin, and moesin) domains of Jak3 interacted with beta-catenin, the NTD domain of bet

148 Thus, we not only characterize Jak3 interaction with beta-catenin but also demonstrate

149 Thus we not only characterize Jak3 interaction with Shc, but also demonstrate the mole

150 Previously we reported that Jak3 interactions with adapter protein p52ShcA (Shc) fac

151 the structural determinants responsible for Jak3 interactions with beta-catenin and determine the fu

152 cellular regulation of Jak3 activation where Jak3 interactions with Shc acted as regulators of Jak3 d

153 JAK3 is a tyrosine kinase that associates with the commo

154 JAK1 is appended to the specific chain, and JAK3 is appended to the common gamma chain.

155 SCID resulting from mutations in IL2RG or JAK3 is characterized by lack of T and natural killer ce

156 TCGA) data showed that reduced expression of JAK3 is correlated with poorer prognosis in melanoma pat

157 ak3 knock-out (KO) mouse model, we show that Jak3 is expressed in colonic mucosa of mice, and the los

158 Numerous studies have demonstrated that Jak3 is widely involved in the activation cascade and fu

159 Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase expressed in both

160 JAK2 and JAK3 isoforms, but not JAK1, mediate CXCL12-induced LFA-

161 lling (67% of cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and BRAF), inactivating lesions disrup

162 d functional selectivity for modulation of a JAK3/JAK1-dependent IL-2 stimulated pathway over a JAK1/

163 ity for cellular transformation, whereas the JAK3 kinase domain mutant could transform cells in a Jak

164 A potent covalent inhibitor of JAK3 kinase was identified with superior selectivity acr

165 Using the Jak3 knock-out (KO) mouse model, we show that Jak3 is ex

166 JAK3 knockdown abrogated lipase activity and epidermal-g

167 inal JAK3 expression during human obesity or JAK3 knockout in mouse or siRNA-mediated beta-catenin kn

168 At the transcriptional level, JAK3 knockout lead to the increased phosphorylation of S

169 testinal epithelium erosion were observed in JAK3 knockout mice.

170 Jak3 KO mice showed reduced expression of colonic villin

171 shed JAK-receptor interaction did not affect JAK3(L857P) activity, whereas it inhibited the other rec

172 In contrast, transduction with JAK3(L857P) induced various types of lymphoid and myeloi

173 e same cytokine receptor independence as for JAK3(L857P) was observed for homologous Leu(857) mutatio

174 or complex to constitutively activate STAT5, JAK3(L857P) was unexpectedly found to not depend on such

175 proved much less potent on cells expressing JAK3(L857P).

176 Leu(857) mutations of JAK1 and JAK2 and for JAK3(L875H).

177 h constitutive activation of Janus kinase 3 (Jak3) leads to different cancers, the mechanism of trans

178 l effect on lymphopoiesis through modulating JAK3 levels.

179 We demonstrate that JAK3 (M511I) can increase its limited oncogenic potentia

180 est that wild-type JAK3 competes with mutant JAK3 (M511I) for binding to the common gamma chain and t

181 additional JAK3-activating mutations such as JAK3(M511I).

182 esity are because of loss of Janus kinase 3 (JAK3)-mediated tyrosine phosphorylation of BCRP.

183 domain of JAK3 (Y100C) completely abrogated JAK3-mediated leukemic transformation.

184 lar interplay between AJ dynamics and EMT by Jak3-mediated NTD phosphorylation of beta-catenin.

185 Our results indicate that JAK3-mediated phosphorylation of BCRP promotes its inter

186 Physiologically, Jak3-mediated phosphorylation of beta-catenin suppressed

187 Moreover, loss of Jak3-mediated phosphorylation sites in beta-catenin abro

188 , which inhibits IL-15 signaling by blocking Jak3, might decrease CD8-dependent pathology.

189 cells/tissues exhibited diminished levels of JAK3 mRNA relative to primary melanoma cells/tissues.

190 histone deacetylase (HDAC)6 inhibition than JAK3 mutant leukemia cells.

191 found IL2Rgamma contributes to constitutive JAK3 mutant signaling by increasing JAK3 expression and

192 provide an explanation of why progression of JAK3-mutant T-ALL cases can be associated with the accum

193 Surprisingly, we observed that one third of JAK3-mutant T-ALL cases harbor 2 JAK3 mutations, some of

194 Pairwise binding between Jak3 mutants and P-villin-wt showed that the FERM domain

195 with bone marrow progenitor cells expressing JAK3 mutants developed a long-latency transplantable T-A

196 s underline the cooperation between JAK1 and JAK3 mutants in T-cell transformation and represent a ne

197 JAK3 mutants induce constitutive JAK/STAT signaling and

198 though JAK3(V674A) and the majority of other JAK3 mutants needed to bind to a functional cytokine rec

199 signaling complex in 293T cells showed that JAK3 mutants required receptor binding to mediate downst

200 These double JAK3 mutants show increased STAT5 activation and increas

201 ansient and stable expression of JAK1 and/or JAK3 mutants showed that each mutant induces STAT activa

202 Most, but not all, JAK3 mutants transformed cytokine-dependent Ba/F3 or MOH

203 lexes in mediating the oncogenic activity of JAK3 mutants.

204 n potentiating oncogenesis in the setting of JAK3-mutation-positive leukemia.

205 our insight into the oncogenic properties of JAK3 mutations and provide an explanation of why progres

206 Our data show that JAK3 mutations are drivers of T-ALL and require the cyto

207 ntial functions, including identification of JAK3 mutations as a cause of SCID.

208 -cell engraftment can occur in patients with JAK3 mutations despite the presence of autologous T cell

209 rt the transforming potential of a series of JAK3 mutations identified in primary T-cell acute lympho

210 ltogether, our results showed that different JAK3 mutations induce constitutive activation through di

211 The study of 3 patients with hypomorphic JAK3 mutations suggests that terminal B-cell maturation/

212 ne third of JAK3-mutant T-ALL cases harbor 2 JAK3 mutations, some of which are monoallelic and others

213 sed the transforming potential of activating JAK3 mutations, whereas absence of IL2Rgamma completely

214 and function of 3 patients with hypomorphic JAK3 mutations.

215 a significant association between SUZ12 and JAK3 mutations.

216 sociated with the accumulation of additional JAK3 mutations.

217 ations, including activating Janus kinase 3 (JAK3) mutations, were detected.

218 rposes of activating PLD2 for cell invasion, JAK3 operates via an alternative pathway that is indepen

219 In contrast, JAK3 or Wnt3a inhibition robustly enhances nuclear facto

220 ts from activating mutations either in JAK1, JAK3, or in both kinases.

221 y exclusive mutations affecting IL2RG, JAK1, JAK3, or STAT5B in 38 of 50 T-PLL genomes (76.0%).

222 JAK3 phosphorylated HuR at tyrosine 200, in turn inhibit

223 d EGFR colocalized at the cell membrane, and JAK3 phosphorylation at Tyr980/Tyr981 followed receptor

224 IRS-2, STAT6, and JAK3 phosphorylation was observed in CHO cells expressin

225 itors delay and reduce IL-7-induced JAK1 and JAK3 phosphorylation.

226 analyses and showed reduced Janus kinase 3 (JAK3) phosphorylation upon activation.

227 ate that conserved IL-2Rgammac signaling via JAK3 plays a key role during early zebrafish lymphopoies

228 xplained for the first time by combined high JAK3/PLD2 phosphorylation and activity involving PLD2's

229 ed cells in culture show an upregulated EGFR/JAK3/PLD2-PA system and are especially sensitive to a co

230 he FERM and SH2 domains of nonphosphorylated Jak3 prevented Jak3 from binding to villin and that tyro

231 However, the SH2 domain of Jak3 prevented P-villin-wt from binding to the FERM doma

232 el, we found that phosphorylation of EZH2 by JAK3 promotes the dissociation of the PRC2 complex leadi

233 interleukin-2 beta receptor (IL-2Rbeta) and JAK3 proteins; however, the association of Lyn with the

234 We tested the transforming properties of JAK3 pseudokinase and kinase domain mutants using in vit

235 JAK3 pseudokinase mutants were dependent on Jak1 kinase

236 t has no off-target effects on IL-2 or IL-15/JAK3/pSTAT5-dependent signaling, which sustain the respo

237 fferentiated human colonic epithelial cells, Jak3 redistributed to basolateral surfaces and interacte

238 In addition, JAK3 regulates cPLA2 phosphorylation independent of tran

239 y through covalent interaction with a unique JAK3 residue Cys-909.

240 , or its direct downstream signaling partner JAK3, result in T and NK cell deficiency, an associated

241 Our data show that loss of Jak3 resulted in increased body weight, basal systemic C

242 mice, and the loss of mucosal expression of Jak3 resulted in reduced expression of differentiation m

243 himerism, and quality of life (QoL) of IL2RG/JAK3 SCID patients >2 years post-HSCT at our center.

244 IL2RG/JAK3 SCID survivors free from immunoglobulin replacement

245 In both IL-2RG- and JAK3-SCID patients, the early stages of lymphoid commitm

246 In vivo treatment of leukemic mice with the JAK3 selective inhibitor tofacitinib reduced the white b

247 n interleukin-2 gamma-chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

248 d protein kinase (MAPK), and Janus kinase 3 (JAK3) signaling are necessary for F. tularensis-induced

249 anti-IL-2Ralpha Ab or inhibitors of JAK1 and JAK3 significantly reduced IFN-gamma production of the T

250 he identification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform spec

251 avorable efficacy and safety profile of this JAK3-specific inhibitor 11 led to its evaluation in seve

252 r cells were, in contrast, more sensitive to JAK3-specific inhibitors.

253 ion mutations targeting PLCG1 (9%) and JAK1, JAK3, STAT3 and STAT5B (JAK/STAT total approximately 11%

254 Here we show that IL-2-JAK3-STAT5 signaling is required for Th9 differentiation

255 Inhibition of IL-2 signaling via Jak3-Stat5 was required during this step to generate CD4

256 els that include IL-2R complex formation and Jak3/Stat5 activation.

257 between at least two signaling pathways: the Jak3/Stat5 and cAMP-mediated cascades.

258 L6 in Th9 cells is under the control of IL-2/JAK3/STAT5 signaling pathway.

259 tion is thought to be driven by constitutive Jak3/Stat5 signaling, mostly due to autocrine production

260 ency mutational activation of the IL2RG-JAK1-JAK3-STAT5B axis in the pathogenesis of T-PLL.

261 Functionally, IL2RG-JAK1-JAK3-STAT5B mutations led to signal transducer and activ

262 tations were associated with immature T-ALL, JAK3/STAT5B mutations in HOXA1 deregulated ALL, PTPN2 mu

263 Most importantly, activation of the JAK3-STAT6 pathway, downstream of IL-4, is required for

264 Effects of IL-4 were mediated via JAK3/STAT6 and we propose a potential role for JAK inhib

265 fibroblast proliferation could be blocked by JAK3/STAT6 signaling selective antagonist.

266 Inhibition of JAK3 suppressed phosphorylation of PI3K downstream effec

267 Moreover, JAK3 suppresses the migration and invasion of cultured m

268 Moreover, a drug screen revealed that JAK3/Suz12 mutant leukemia cells were more sensitive to

269 wever, in 2-h or 16-h starved cell cultures, JAK3 switches to a PLD2-enhancing role, consistent with

270 Consistent with a role of JAK3 in GVHD, Jak3(-/-) T cells caused less severe GVHD.

271 kinases (PKC, FES, EGF receptor (EGFR), and JAK3) that are activated by it, or PLD becomes the targe

272 d pave the way toward multitargeted JAK1 and JAK3 therapy in T-ALL.

273 Both ASB2 and SKP2 can interact with JAK3 through different domains; the FERM and pseudo-kina

274 ve and metastatic, did not substantially use JAK3 to activate PLD2.

275 inactivation of Suz12 cooperates with mutant JAK3 to drive T-cell transformation and T-ALL developmen

276 horylation was the rate-limiting step during Jak3 trans-phosphorylation of beta-catenin, where Jak3 d

277 horylation was the rate-limiting step during Jak3 trans-phosphorylation of Shc where Jak3 directly ph

278 he biological significance of NOTCH-mediated JAK3 turnover.

279 degree of allelic heterogeneity at the human JAK3, TYK2, STAT1, and STAT3 loci has revealed highly di

280 nd humans carrying biallelic null alleles of JAK3, TYK2, STAT1, or STAT5B.

281 The Janus kinase 3 (JAK3) tyrosine kinase is mutated in 10% to 16% of T-cell

282 hemical mechanisms involved in NOTCH-induced JAK3 ubiquitination and degradation.

283 Together, these results suggest that JAK3 ubiquitination involves the non-canonical dimeric E

284 ase activity by recombinant full-length (wt) Jak3 using Jak3-wt or villin/gelsolin-wt as substrate sh

285 Although JAK3(V674A) and the majority of other JAK3 mutants neede

286 nsduction of murine hematopoietic cells with JAK3(V674A) led homogenously to lymphoblastic leukemias

287 cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expres

288 y three mutations, which encoded NRAS(A18T), JAK3(V722I) and MET(R970C) in three specimens.

289 inome selectivity, including selectivity for JAK3 versus JAK1, and good biopharmaceutical properties.

290 Functionally Jak3 was autophosphorylated under IL-2 stimulation in ep

291 Previously, we reported that Jak3 was essential for mucosal differentiation and enhan

292 Mechanistically, Jak3 was essential for reduced expression and activation

293 d P-villin-wt showed that the FERM domain of Jak3 was sufficient for binding to P-villin-wt with a K(

294 and Shc showed that although FERM domain of Jak3 was sufficient for binding to Shc, CH1 and PID doma

295 and the results showed that Janus kinase 3 (JAK3) was with reduced expression in the metastatic line

296 by acquiring another activating mutation in JAK3, whereas cells that originally showed a JAK3-activa

297 2 (PLD2) is under control of Janus kinase 3 (JAK3), which mediates chemotaxis.

298 ic parameters showed that phosphorylated (P) Jak3-wt binds to P-villin-wt with a dissociation constan

299 y by recombinant full-length (wt) Jak3 using Jak3-wt or villin/gelsolin-wt as substrate showed that J

300 gamma interaction site in the FERM domain of JAK3 (Y100C) completely abrogated JAK3-mediated leukemic